Skip to content

Psychopharmacology (Berl)

ISSN 0033-3158; 1432-2072;

27 papers in the library · 1,507 citations · publishing 1977-2026

Papers

Sort Most recent Most cited

Shorter to be effective: subanesthetic-dose ketamine infusion reduces the global and regional path length of brain functional connectivity in patients with treatment-resistant depression and suicidal ideation.

Psychopharmacology (Berl) May 22, 2026 Wei-Chen Lin, Li-Kai Cheng, Tung-Ping Su et al.

Shorter to be effective: subanesthetic-dose ketamine infusion reduces the global and regional path length of brain functional connectivity in patients with treatment-resistant depression and suicidal ideation.

DOI: 10.1007/s00213-026-07089-6 (opens in new tab)

Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.

Psychopharmacology (Berl) November 1, 2024 Lisa Jerome, Allison A. Feduccia, Julie B. Wang et al. 10 citations

Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.

DOI: 10.1007/s00213-024-06665-y (opens in new tab) Full text (opens in new tab) Therapeutic method Innovative approach PTSD Symptom Relief PTSD Recovery +7

Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Psychopharmacology (Berl) November 1, 2024 Michael C Mithoefer, Allison A. Feduccia, Lisa Jerome et al. 9 citations

Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

DOI: 10.1007/s00213-024-06666-x (opens in new tab) Full text (opens in new tab) Significantly reduce symptoms Innovative treatment strategy Effective PTSD Treatment MDMA-Assisted Psychotherapy MDMA +4

Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.

Psychopharmacology (Berl) November 1, 2024 Allison A. Feduccia, Lisa Jerome, Michael C Mithoefer et al. 6 citations

Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.

DOI: 10.1007/s00213-024-06671-0 (opens in new tab) Full text (opens in new tab) Psychedelic therapy MDMA Psychotherapy MDMA-Assisted Therapy Ecstasy therapy +23

Effects of a dissociative drug on fronto-limbic resting-state functional connectivity in individuals with posttraumatic stress disorder: a randomized controlled pilot study.

Psychopharmacology (Berl) October 23, 2023 Sarah K. Danböck, Or Duek, Ziv Ben-Zion et al. 6 citations

Effects of a dissociative drug on fronto-limbic resting-state functional connectivity in individuals with posttraumatic stress disorder: a randomized controlled pilot study.

DOI: 10.1007/s00213-023-06479-4 (opens in new tab) Full text (opens in new tab)

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.

Psychopharmacology (Berl) March 29, 2022 Manon M.j. van den Berg, Igor Magaraggia, Rudy Schreiber et al. 14 citations

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.

DOI: 10.1007/s00213-022-06106-8 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Antidepressants Brain research

Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil.

Psychopharmacology (Berl) February 18, 2022 Dimitri Daldegan-Bueno, Lucas Oliveira Maia, Carolina Marcolino Massarentti et al.

RationaleSmoking-related disease is a major problem globally. Effective smoking cessation treatments are however limited. Increasing evidence suggests that psychedelics have potential as treatments for substance use disorders and may therefore prove an option in aiding smoking cessation.ObjectivesTo establish which factors predict smoking cessation in people who reported quitting or reducing...

DOI: 10.1007/s00213-022-06063-2 (opens in new tab) Ayahuasca Psychedelic Hallucinogen Smoking cessation +9

Therapeutic effect of an ayahuasca analogue in clinically depressed patients: a longitudinal observational study.

Psychopharmacology (Berl) January 24, 2022 Kim van Oorsouw, S. W. Toennes, J. G. Ramaekers 71 citations

RATIONALE: Studies have suggested mental health improvements following the use of the psychotropic plant concoction ayahuasca in non-clinical and clinical samples. OBJECTIVES: The present observational study assessed depressive symptomatology in 20 clinically depressed patients (symptom score > 13 on the Beck's Depression Inventory) before attendance of an ayahuasca ceremony and 1 month and 1...

DOI: 10.1007/s00213-021-06046-9 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Ayahuasca Depression treatment Antidepressant +18

Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.

Psychopharmacology (Berl) November 4, 2021 Joanna Kuć, Hannes Kettner, Fernando E. Rosas et al. 37 citations

RATIONALE: Classic psychedelics are currently being studied as novel treatments for a range of psychiatric disorders. However, research on how psychedelics interact with other psychoactive substances remains scarce. OBJECTIVES: The current study aimed to explore the subjective effects of psychedelics when used alongside cannabis. METHODS: Participants (n = 321) completed a set of online surveys...

DOI: 10.1007/s00213-021-05999-1 (opens in new tab) Full text (opens in new tab) Psychedelics Cannabis/marijuana/weed Drug interactions Altered states +1

Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.

Psychopharmacology (Berl) November 21, 2020 Allison A. Feduccia, Lisa Jerome, Michael C Mithoefer et al. 39 citations Retracted

Abstract Rationale MDMA-assisted psychotherapy is under investigation as a novel treatment for posttraumatic stress disorder (PTSD). The primary mechanism of action of MDMA involves the same reuptake transporters targeted by antidepressant medications commonly prescribed for PTSD. Objectives Data were pooled from four phase 2 trials of MDMA-assisted psychotherapy. To explore the effect of...

DOI: 10.1007/s00213-020-05710-w (opens in new tab) Full text (opens in new tab) Psychedelic therapy Psychedelic-assisted therapy MDMA-Assisted Psychotherapy Antidepressant discontinuation +10

A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.

Psychopharmacology (Berl) April 13, 2019 Malin V. Uthaug, R. Lancelotta, Kim van Oorsouw et al. 198 citations

A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.

DOI: 10.1007/s00213-019-05236-w (opens in new tab) Full text (opens in new tab) Mental health Psychological health Emotional well-being Mental wellness +25

Progress and promise for the MDMA drug development program.

Psychopharmacology (Berl) November 20, 2017 Allison A. Feduccia, Julie Holland, Michael C Mithoefer 79 citations

Pharmacotherapy is often used to target symptoms of posttraumatic stress disorder (PTSD), but does not provide definitive treatment, and side effects of daily medication are often problematic. Trauma-focused psychotherapies are more likely than drug treatment to achieve PTSD remission, but have high dropout rates and ineffective for a large percentage of patients. Therefore, research into drugs...

DOI: 10.1007/s00213-017-4779-2 (opens in new tab) Psychedelic therapy MDMA Therapy MDMA-Assisted Psychotherapy MDMA Treatment +21

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.

Psychopharmacology (Berl) November 8, 2017 R. L. Carhart-Harris, Mark Bolstridge, C. M. J. Day et al. 978 citations

RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major...

DOI: 10.1007/s00213-017-4771-x (opens in new tab) Full text (opens in new tab) Psychedelic therapy Treatment-resistant depression Psilocybin therapy Psilocybin-assisted treatment +17

MDMA: a social drug in a social context.

Psychopharmacology (Berl) October 5, 2014 Matthew G. Kirkpatrick, Harriet de Wit 43 citations

RationaleThe drug ±3,4-methylenedioxymethamphetamine (MDMA, "ecstasy," "molly") is thought to produce prosocial effects and enhance social interaction. However, in most laboratory studies to date, the participants have been tested under nonsocial conditions, which may not simulate the effects the drug produces in more naturalistic social settings.MethodsHealthy experienced MDMA users...

DOI: 10.1007/s00213-014-3752-6 (opens in new tab) Full text (opens in new tab)